Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06369155 · ClinicalTrials.gov registry record · Phase 2
Azenosertib in Uterine Serous Carcinoma: Biomarker Study
A Phase 2 study of Uterine Cancer and Uterine Serous Carcinoma, sponsored by Joyce Liu, MD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 2
- Study locations
NCT06369155: Recruiting Phase 2 study of Uterine Cancer and Uterine Serous Carcinoma, sponsored by Joyce Liu, MD.
NCT06369155 is a Phase 2 study of Uterine Cancer and Uterine Serous Carcinoma that is actively recruiting participants, run by Joyce Liu, MD. The registered enrollment target is 25 participants, below the 270-participant average among 27 other Uterine Cancer trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06369155, a Phase 2 study of Uterine Cancer and Uterine Serous Carcinoma, is actively recruiting participants, sponsored by Joyce Liu, MD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research study is being done to investigate how Azenosertib affects tumor cells of persistent or recurrent uterine serous carcinoma. The name of the study drug involved in this study is: -Azenosertib (a type of Wee1 inhibitor)
Primary Outcome
Replication fork speed assessed by DNA fiber assays in PDO models. Responder defined as participants achieving complete response (CR) or partial response (PR) based on RECISTv1.1 criteria. Wilcoxon rank sum tests will be used to compare the percentage change in replication fork speed with exposure to WEE1 inhibition in co-clinical models between overall response responder and non-responder.
Conditions Studied
Interventions
- DRUG Azenosertib
Study Locations (2)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2025-03-05 |
| Est. Completion | 2028-01-31 |
| Phase | Phase 2 |
What NCT06369155 shows while recruiting
NCT06369155 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 270-participant average among 27 other Uterine Cancer trials with a reported enrollment target (91% lower).
The record links to 3 conditions, with Uterine Cancer appearing as the primary indexed condition, and to 1 intervention - of which Azenosertib is the first listed.
NCT06369155 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06369155 about?
NCT06369155 is a clinical study titled "Azenosertib in Uterine Serous Carcinoma: Biomarker Study". This research study is being done to investigate how Azenosertib affects tumor cells of persistent or recurrent uterine serous carcinoma. The name of the study drug involved in this study is: -Azenosertib (a type of Wee1 inhibitor)
What is the current status of trial NCT06369155?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2025-03-05. Estimated completion is 2028-01-31.
What conditions does trial NCT06369155 study?
This clinical trial studies the following conditions: Uterine Cancer, Uterine Serous Carcinoma, Uterine Carcinoma.
What interventions are being tested in trial NCT06369155?
The interventions under investigation include: Azenosertib (DRUG).
Who is sponsoring clinical trial NCT06369155?
This trial is sponsored by Joyce Liu, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06369155 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uterine Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06369155's enrollment target sits among peer trials
25 22nd of 27 higher than 5 of 27 other Uterine Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Uterine Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PROton Therapy for Post Surgical Treatment of GYNecologic Cancer
RECRUITING · Phase 2
-
[18F]FES PET/.CT in Uterine Cancer
RECRUITING · Phase 2
-
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
RECRUITING · Phase 2
-
AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Nivolumab in Selected Uterine Cancer Patients
COMPLETED · Phase 2
-
Image-Guided Gynecologic Brachytherapy
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI